A Billion-Dollar Aldosterone Synthase Inhibitor, an Oral KRASG12D Inhibitor Entering Development, and 14 More Molecules in the News

In this update of small molecules in the news we will cover recent:

  • (B)Million Dollar Molecules: recent mergers and acquisitions
  • Molecules in Motion: clinical trial updates and FDA filings
  • Molecules of the Month – Where Are They Now?: updates on past Drug Hunter MotM
  • Potential upcoming approvals: recent NDA filings and upcoming PDUFA dates

Want updates like this straight to your inbox? Sign up for our weekly newsletter here.

Million-Dollar Molecules


This highly selective, oral aldosterone synthase (CYP11B2) inhibitor is being acquired by AstraZeneca via CinCor in a $1.8B transaction. The molecule is in several Ph. II trials (0.5-2 mg QD) for hypertension, CKD, and primary aldosteronism, appears to have demonstrated dose-dependent PK/PD and blood pressure response, and appears to be well-tolerated so far. CinCor licensed the molecule from Roche (RO6836191).


oral aldosterone synthase (CYP11B2) inhibitor

acquired by AstraZeneca from CinCor for $1.8B

request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.

already a member? log in:

Join the Drug Hunter mailing list

to get free content and resources weekly. Trusted by > 5,500 drug hunters worldwide. Unsubscribe anytime.


Join Subscribers from

…and hundreds more!